$200M SPAC fund­ed by bil­lion­aire Michael Dell will un­wind af­ter fail­ing to find a part­ner

The bio­phar­ma in­dus­try may be do­ing deals again, but SPACs are be­ing left out of the re­cent wave.

Ori­on Biotech Op­por­tu­ni­ties Corp., a blank check ve­hi­cle fund­ed in part by tech bil­lion­aire Michael Dell’s fam­i­ly firm, an­nounced Mon­day it will dis­solve on May 17 and re­turn in­vest­ments to share­hold­ers af­ter be­ing un­able to find a merg­er part­ner. As of April 20, the SPAC’s trust ac­count held rough­ly $205 mil­lion, ac­cord­ing to a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER